Artwork for Cost-effectiveness of Aflibercept vs Bevacizumab-First Therapy for Diabetic Macular Edema
JAMA Ophthalmology Author Interviews

Cost-effectiveness of Aflibercept vs Bevacizumab-First Therapy for Diabetic Macular Edema
00:00:00 / 00:13:02